Respond to prefers-color-scheme dark in app web views

Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

Show NLP summaries collection recirc on article pages

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

Look to the cloud to protect the life documents saved on your computer

Can you spot bad financial advice on TikTok? Take our quiz.

5 myths about Social Security as the program faces a funding crisis

Elections 2024 live updates: Biden continues outreach to Black voters; Trump heading to Minnesota

At campus protests, ‘DO NOT TALK TO THE MEDIA’!

CNN gets a presidential debate — and a much-needed win

Puppy abandoned with heart-rending note is adopted, named Minerva

Man, 91, shocks tiny firehouse with $500K gift: ‘Nobody knew how much I’d saved’

Retired cop meets abandoned baby he helped 23 years ago: ‘What are the odds?’

The world’s coolest hotels want to tell you a story

6 Airbnb red flags to spot before you make a booking mistake

Some cruise prices are about to get a little more clear

Why this company’s biggest fans turned against it

These ISIS news anchors are AI fakes. Their propaganda is real.

Even remote and hybrid work can burn you out. Here’s how to avoid it.

Tariffs against China hamstring the transition to a clean energy future

The Post’s choices in Northern Virginia’s U.S. House primaries

States see legalized sports betting as a tax windfall — but at what cost?

Did Trump’s lawyers catch Michael Cohen in a ‘lie’? Let’s take a look.

Now playing off-Broadway: Trump’s synchronized sycophants

Trump’s courtroom enablers

In photos: The scene in Houston after severe storms killed at least 4 people

Rep. AOC's 'people-first' approach

Rep. Delia Ramirez on organizing power and money

Bryce Harper, Joey Gallo and a bond forged by baseball since they were kids

Walter Johnson’s jersey from 1920 showdown with Babe Ruth is up for auction

A taco will always be a taco — no matter what we call it

Miss Manners: Longtime friends lose minds over canceled dinner plans

Carolyn Hax: After holiday meals, guests rush the kitchen to claim the leftovers

Ask Amy: Retired couple misses social activities since the pandemic

No one is rocking in the ‘free world’

Kenyan president aims to attract green investment during U.S. visit

On Gaza, Biden is right and Netanyahu is wrong

Trump

Healthy living, including food, fitness, longevity and mental health

See more coverage in your recommendations

See alerts for Health and Wellness developments

Health & wellness

Tips on living better delivered every Thursday

Well+Being newsletter

Health alerts

Health & Science alerts

EDITORS - THIS IMAGE WAS PROVIDED BY A THIRD PARTY. DENMARK OUT. NO COMMERCIAL OR EDITORIAL SALES IN DENMARK.

Ritzau Scanpix

Novo Nordisk booked its highest annual profit in decades, lifted by the booming sales of its diabetes and obesity drugs like Ozempic and Wegovy, the company reported Wednesday.

The Denmark-based drugmaker also said it is boosting supplies of Wegovy in the United States, potentially alleviating persistent shortages of the blockbuster obesity drug.

“We are now enabling more U.S. patients to initiate treatment by more than doubling the amount of lower-dose strengths,” Doug Langa, executive vice president of Novo’s North America operations, said on a call with analysts. The company had restricted starting doses for new patients last May to ensure there would be enough supply for continuing patients.

Novo executives said Wednesday they plan to gradually increase supply throughout 2024, but their forecast allows for periodic supply constraints. As of Wednesday, the U.S. Food and Drug Administration listed semaglutide — the main ingredient in Ozempic and Wegovy — on its <a href="https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=c" target=_blank>shortage list</a>.

Novo and rival Eli Lilly have established themselves as the leaders in what some Wall Street analysts predict will be the best-selling class of drugs of all time — appetite suppressing compounds known as GLP-1 drugs, which mimic a naturally occurring hormone that sends a signal of fullness to the brain. The drugs are injected once weekly, but the race is on to develop pill versions.

The boom in imitation Ozempic went bust for one pharmacy and its clients

Demand for the drugs has been so hot that Novo has struggled to churn out enough, leading the FDA to declare a shortage of semaglutide in March 2022. That designation has opened the door for specialized pharmacies to make copies of the FDA-approved drug, <a href="https://www.washingtonpost.com/business/2023/09/19/ozempic-semaglutide-compounding-pharmacies/" target="_blank">propping up an industry</a> of clinics and telehealth firms that sell the pharmacy-made versions at a discount.

Novo turned an annual profit of 83.7 billion in Danish kroner in 2023, 51 percent higher than the previous year and equivalent to about $12 billion at current exchange rates. That marks the company’s largest annual net profit going back to 1989, according to data from S&amp;P Global Market Intelligence.

Ozempic alone accounted for 41 percent of Novo’s total sales in 2023, equivalent to more nearly $14 billion, with two-thirds of the drug’s sales coming from the United States. Wegovy brought in sales of about $4.5 billion.

“We are very pleased with the strong performance in 2023 reflecting that more than 40 million people are now benefiting from our innovative diabetes and obesity treatments,” Lars Fruergaard Jørgensen, Novo’s chief executive, said in a statement.

University of Chicago, BA in International Studies

Daniel Gilbert joined The Washington Post in 2022 and writes about the business of medicine. He previously spent seven years as an investigative reporter for the Seattle Times, and before that covered business and energy for the Wall Street Journal.

Daniel Gilbert

Novo Nordisk profit surges as it boosts supplies of Wegovy

the-washington-post

Novo Nordisk CEO, Lars Fruergaard Joergensen talks to the press at Novo Nordisk headquarters in Bagsvaerd

via REUTERS

name

washpost

prism://prism.query/site-articles-only,/business&limit=20

Get a curated selection of 10 of our best stories in your inbox every weekend.

Business

The source for business news and analysis. Covering economic policy, business policy, financial news, economic issues, stock market data, local business, technology and more.

prism://prism.query/site,/health&limit=20

Health

The Washington Post health section provides coverage and analysis of health, healthcare, nutrition and fitness news.

Well+Being

Well+Being from The Washington Post covers healthy living, including nutrition, fitness, mental health, relationships, chronic illness and disability.

Live well every day with tips and guidance on food, fitness and mental health, delivered to your inbox every Thursday.